Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab SC dosing schedules in SLE
NCT00732940Phase 2Terminated
- Sponsor
- Human Genome Sciences
- Start
- Oct 2008
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of belimumab in systemic lupus erythematosus (SLE), sponsored by Human Genome Sciences. Started Oct 2008; status: terminated.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00732940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00732940.